Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
TGTX TG Therapeutics	$36.72 -3.2%	$37.05	$16.65 ▼ $47.61	$5.83B	1.94	2.91 million shs	2.47 million shs
TLX Telix Pharmaceuticals	$16.00 -2.4%	$17.02	$13.61 ▼ $30.36	$5.41B	N/A	28,343 shs	21,786 shs
VERA Vera Therapeutics	$22.65 -2.7%	$22.62	$18.53 ▼ $51.61	$1.44B	1.13	974,176 shs	2.68 million shs
VRNA Verona Pharma PLC American Depositary Share	$93.82 -0.6%	$78.39	$14.15 ▼ $99.01	$7.99B	0.21	1.26 million shs	951,387 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
TGTX TG Therapeutics	0.00%	+1.94%	+3.96%	-6.87%	+106.41%
TLX Telix Pharmaceuticals	0.00%	-6.71%	-4.50%	-4.53%	+1,599,999,900.00%
VERA Vera Therapeutics	0.00%	+8.58%	+19.09%	-5.70%	-37.40%
VRNA Verona Pharma PLC American Depositary Share	0.00%	-0.53%	+16.07%	+47.77%	+548.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
TGTX TG Therapeutics	3.618 of 5 stars	2.4	1.0	0.0	3.5	1.6	2.5	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	3.5017 of 5 stars	4.6	1.0	0.0	0.0	2.9	4.2	0.0
VRNA Verona Pharma PLC American Depositary Share	1.7014 of 5 stars	2.5	1.0	0.0	0.0	3.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	11.11% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.00	37.50% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	186.98% Upside
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$101.10	7.76% Upside

Current Analyst Ratings Breakdown

Latest VERA, TGTX, TLX, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	VRNA Verona Pharma PLC American Depositary Share	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$76.00 ➝ $160.00
6/20/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $138.00
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/3/2025	VERA Vera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $65.00
6/2/2025	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $85.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
TGTX TG Therapeutics	$329M	17.72	$0.12 per share	306.10	$1.43 per share	25.68
TLX Telix Pharmaceuticals	$516.72M	10.48	$0.11 per share	140.11	$1.12 per share	14.29
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A
VRNA Verona Pharma PLC American Depositary Share	$42.28M	188.90	N/A	N/A	$2.56 per share	36.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
TGTX TG Therapeutics	$23.38M	$0.24	153.00	36.72	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	33.33	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,127.33	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest VERA, TGTX, TLX, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
TGTX TG Therapeutics	1.03	4.02	3.04
TLX Telix Pharmaceuticals	0.99	2.78	2.66
VERA Vera Therapeutics	0.10	27.68	27.68
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
TGTX TG Therapeutics	58.58%
TLX Telix Pharmaceuticals	N/A
VERA Vera Therapeutics	99.21%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
TGTX TG Therapeutics	10.64%
TLX Telix Pharmaceuticals	N/A
VERA Vera Therapeutics	16.30%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.38 million	N/A	N/A
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

VERA, TGTX, TLX, and VRNA Headlines

Recent News About These Companies

SG Americas Securities LLC Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 26, 2025 | marketbeat.com

HBK Sorce Advisory LLC Sells 3,800 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 25, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 52-Week High on Analyst Upgrade

June 25, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High After Analyst Upgrade

June 23, 2025 | marketbeat.com

Piper Sandler Forecasts Strong Price Appreciation for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock

June 23, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLC

June 22, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Price Target Raised to $138.00 at Wells Fargo & Company

June 21, 2025 | americanbankingnews.com

Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects

June 20, 2025 | msn.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Roth Capital Reiterates Buy Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 20, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of Stock

June 19, 2025 | insidertrades.com

Mission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 19, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

June 18, 2025 | marketbeat.com

Verona Pharma: An Impressive Initial Launch

June 18, 2025 | seekingalpha.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

June 18, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?

June 16, 2025 | marketbeat.com

Traders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 16, 2025 | marketbeat.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 14, 2025 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 14, 2025 | insidertrades.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 13, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 Shares

June 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
5 Small Cap Stocks With Explosive Upside Potential
By Ryan Hasson | June 23, 2025
View 5 Small Cap Stocks With Explosive Upside Potential

VERA, TGTX, TLX, and VRNA Company Descriptions

TG Therapeutics NASDAQ:TGTX

$36.72 -1.23 (-3.24%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$47.61 +10.89 (+29.66%)

As of 04:00 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Telix Pharmaceuticals NASDAQ:TLX

$16.00 -0.40 (-2.44%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.00 -0.01 (-0.03%)

As of 06/27/2025 04:04 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Vera Therapeutics NASDAQ:VERA

$22.65 -0.64 (-2.75%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.40 -1.25 (-5.52%)

As of 04:00 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$93.82 -0.58 (-0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$93.51 -0.31 (-0.33%)

As of 06/27/2025 07:59 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time